secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023827
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q3 2022 net loss $28.3M; cash $395.1M; NKX019 dose expansion opened
--------------------------------------------------------------------------

- Net loss of $28.3M ($0.58 per share); R&D expense $23.4M, G&A $6.8M.
- Cash, equivalents, and investments $395.1M; expected to fund operations into 2025.
- NKX019 dose expansion cohorts opened; clinical update expected by year-end 2022.
- NKX101 data for r/r AML timeline pushed to first half of 2023.
- SITC presentations on NKX019+CD20 mAb combination and scalable NK cell manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/0000950170-22-023827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022023827/nktx-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer